Answers are grounded in this paper and cite their sources.
To determine whether astrocyte-derived small extracellular vesicles (sEVs) deliver Serpina3k to recipient neural cells and protect against cerebral ischemia-reperfusion injury (CIRI). A mouse transient middle cerebral artery occlusion/reperfusion model was combined with pharmacological inhibition of sEV release, astrocyte-targeted Serpina3k knockdown and intrathecal delivery of astrocyte-derived sEVs. Brain sEV cargo was profiled by label-free proteomics and Transwell co-cultures were subjected to oxygen-glucose deprivation/reoxygenation. Neurological outcomes, infarct volume, apoptosis and inflammatory mediators were assessed, and Serpina3k-interacting proteins were identified by co-immunoprecipitation. Blocking sEV release aggravated neurological deficits, neuronal apoptosis and inflammation. Brain-derived sEVs increased after ischemia-reperfusion and protected neurons against oxygen-glucose deprivation/reoxygenation. Serpina3k was enriched in ischemia-derived sEVs and localized predominantly to astrocytes; astrocytic Serpina3k knockdown reduced sEV-associated Serpina3k and worsened deficits, whereas Serpina3k-deficient sEVs increased neuronal apoptosis, microglial IL-1beta and IL-18 release, infarct volume and Caspase-6/NLRP3 signalling. Serpina3k co-immunoprecipitated with Caspase-6 and Omi/HtrA2. In vivo, Serpina3k-deficient astrocytic sEVs were associated with larger infarct volume, increased Omi/HtrA2 expression and reduced HAX-1 expression. Astrocyte-derived sEV-associated Serpina3k is an endogenous protective cargo that limits cerebral ischemia-reperfusion injury by restraining microglial inflammatory activation and neuronal apoptosis.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: